Skip to NavigationSkip to content

AbbVie's Rinvoq hits target in psoriatic arthritis sub-population at Phase 3

Published on 06/02/20 at 12:49pm

AbbVie has unveiled new Phase 3 data on its selective and reversible JAK inhibitor Rinvoq (upadacitinib) in the treatment of active psoriatic arthritis in adults who have responded inadequately or are intolerant to one or more non-biologic disease modifying anti-rheumatic drugs (DMARDs).

The results revealed that 71% of patients receiving 15mg Rinvoq and 79% receiving 30mg achieved an ACR20 response after 12 weeks of treatment compared to 36% with placebo, meeting the trial’s primary endpoint. Furthermore, Rinvoq proved non-inferior to adalimumab after 12 weeks in the 15mg dose, while the 30mg dose proved superior.

An ACR50 response was achieved after 12 weeks by 38% with 15mg and 52% with 30mg compared to 13% with placebo, while ACR70 was achieved by 16% and 25% respectively compared to 2% with placebo.

Skin symptoms were also reduced in both groups, with 62% and 63% of the 15mg and 30mg groups achieving a 75% improvement as measured by the Psoriasis Area Severity Index (PASI 75).

"The results of SELECT-PsA 1 showed that both doses of upadacitinib demonstrated significantly greater efficacy in joint and skin symptoms, as well as inhibition of radiographic progression, compared to placebo," remarked Dr Professor Iain McInnes, University of Glasgow Institute of Infection, Immunity & Inflammation. "These data are encouraging and add to the growing body of evidence that upadacitinib has the potential to improve outcomes for people living with psoriatic arthritis."

Dr Michael Severino, Vice Chairman and President at AbbVie, also commented on the results: "Patients living with psoriatic arthritis often suffer from joint pain, stiffness and fatigue, impacting their ability to work and lead a physically active life. The results of this large Phase 3 study further support the potential of Rinvoq to help these patients. We look forward to sharing these data with regulatory bodies around the world to support our application for label expansion for Rinvoq to include adult patients with active psoriatic arthritis."

Matt Fellows

Comments

It was the happiest news to know that AbbVie has unveiled its new Phase 3 data on its selective and reversible JAK inhibitor Rinvoq. More about the news is given in the post which will be helpful for people who would like to know about this in detail cbd coffee

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches